We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.
Cambridge, United States
Founded in 2020
1-10 Employees
Startup
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
Biotechnology, Health Care, Therapeutics
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
PAQ Therapeutics operates in 1 country around the world
Get an overview of the locations of PAQ Therapeutics
Location
Country
State
City
Headquarter
United States
Massachusetts
Cambridge
Some frequent questions that have been asked about PAQ Therapeutics
Where is PAQ Therapeutics located?
The company headquarter of PAQ Therapeutics is located in Cambridge, Massachusetts, United States. It's worth noting, that the company may have more locations
How many employees does PAQ Therapeutics approximately have?
As of the latest available information PAQ Therapeutics has around 1-10 employees worldwide.
When was PAQ Therapeutics founded?
PAQ Therapeutics was founded in 2020
In which industries does PAQ Therapeutics mainly work?
The company PAQ Therapeutics has it's main focus in the industries of Biotechnology
What is the current company status of PAQ Therapeutics?
Based on the founding year and the amount of employees the company PAQ Therapeutics seems to be a Startup at the current state. Note that over time that status can change
Check out some interesting alternative companies to PAQ Therapeutics
Proteovant Therapeutics
Philadelphia, United States
11-50 Employees
2021
The power of protein degradation is now being realized. This innate cellular process is responsible for maintaining protein homeostasis, and we are now exploiting it to break down the proteins that cause disease. The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Development of the best, most effective medicines for patients requires extensive biology insight, medicinal chemistry experience, drug discovery expertise and cutting-edge computational tools such as artificial intelligence and machine learning. Proteovant is leveraging targeted protein degradation to discover and develop transformative medicines for the treatment of patients with life-altering diseases.
Avilar Therapeutics
Waltham, United States
11-50 Employees
-
We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We are building an organization that is taking science to new limits and has respect for everyone. We have built a bespoke, integrated, and modular drug discovery platform to enable the design and assembly of ATACs targeting a wide array of extracellular proteins.
Orum Therapeutics
Kazan, Russia
11-50 Employees
2016
We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.
16250 - 1st TPD Europe 2020
London, United Kingdom
1-10 Employees
-
As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.
Vivoryon Therapeutics
Halle (Saale), Germany
101-250 Employees
1997
We are focused on developing innovative small molecule-based medicines. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings.
Lycia Therapeutics
San Diego, United States
11-50 Employees
2019
To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.